The Ranitidine Oral Solution, cataloged under National Stock Number 6505-01-312-2953, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Glaxosmithkline Pharmaceuticals. Government technical data includes 4 specifications, cited from the U.S. Government catalog. The record lists 1 manufacturer part number for this item, enabling identification through both NSN and commercial part number lookups. 2 additional reference documents (drawings, advisory and superseded references) are recorded in the U.S. Government catalog. Current acquisition status: Active. Unit of issue: BT.
| Parameter | Value |
|---|---|
| NSN | 6505-01-312-2953 |
| Primary Part Number | ZANTAC SIR 150MG/10ML 2X280ML |
| Item Name | Ranitidine Oral Solution |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Glaxosmithkline Pharmaceuticals |
| Status | ACTIVE |
| Primary Container Content Quantity | 16.000 FLUID OUNCES OR 473.000 MILLILITERS |
| Medical Designation and Grade | UNITED STATES PHARMACOPEIA |
| Primary Container Type | BOTTLE |
| Active Medicament Medicinal Strength | 15.000 MILLIGRAMS RANITIDINE EQUIVALENT PER MILLILITER |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Unit of Issue | BT |
| Part Number | Manufacturer |
|---|---|
| ZANTAC SIR 150MG/10ML 2X280ML | Glaxosmithkline Pharmaceuticals (BEL) |
| Reference | Meaning |
|---|---|
| 0680090 | 6/9 Informative reference only Association Pharmaceutique Belge-Algemene Pharmaceutische Bond |
| NDC00121-0727-16 | 3/9 Design control — primary reference Pharmaceutical Associates, Inc. Dba Pai |
NSN 6505-01-312-2953 is a Ranitidine Oral Solution, manufactured by Glaxosmithkline Pharmaceuticals, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-312-2953 has 1 manufacturer part number on file: ZANTAC SIR 150MG/10ML 2X280ML (Glaxosmithkline Pharmaceuticals).
Key specifications for ZANTAC SIR 150MG/10ML 2X280ML: Primary Container Content Quantity: 16.000 FLUID OUNCES OR 473.000 MILLILITERS; Medical Designation and Grade: UNITED STATES PHARMACOPEIA; Primary Container Type: BOTTLE; Part Name Assigned by Controlling Agency: RANITIDINE ORAL SOLUTION USP 15MG/ML 16FL OZ OR 473ML BT.. 4 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.